The effects of omega-3 fatty acids supplementation on hemoglobin, hematocrit, and platelet levels of patients with ESRD condition undergoing dialysis

Concomitant inflammation may boost the cardiovascular complications in end-stage renal disease (ESRD) patients undergoing hemodialysis (HD). Omega-3 fatty acids may have certain health benefits in HD patients. The aim of this study was to investigate the effects of omega-3 fatty acids supplementatio...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of translational autoimmunity (Online) Vol. 8; p. 100233
Main Authors:	Mahmoudi, Zahra, Roumi, Zahra, Askarpour, Seyed Ali, Mousavi, Zahra, Shafaei, Hanieh, Valisoltani, Neda, Shapouri, Mahsa, Mirshafaei, Seyed Reza, Mirzaee, Pouya, Mobarakeh, Khadijeh Abbasi, Taghavi Sufiani, Elahe, Nowdehi, Zahra Mohammadi, Motiei, Zeynab, Khosravi, Masoud, Doaei, Saeid, Gholamalizadeh, Maryam
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier B.V 01-06-2024 Elsevier
Subjects:	Chronic kidney disease Hematocrit Hemodialysis Hemoglobin Omega-3 fatty acids Platelet Hemoglobin Platelet Chronic kidney disease Hemodialysis Omega-3 fatty acids Hematocrit
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Concomitant inflammation may boost the cardiovascular complications in end-stage renal disease (ESRD) patients undergoing hemodialysis (HD). Omega-3 fatty acids may have certain health benefits in HD patients. The aim of this study was to investigate the effects of omega-3 fatty acids supplementation on hematocrit (HCT), hemoglobin (HB) level and platelet (PLT) counts of HD patients. A randomized controlled trial was conducted on HD patients at a private dialysis center in Rasht, Iran. Three omega-3 fatty acid supplement capsules (3 g/d) were administered daily for two months to patients in the intervention group (n = 55). The control group (n = 60) were given three placebo capsules containing medium chain triglyceride (MCT) oil, similar to the supplemental dose of the intervention group at the same period. Three parameters of HCT, HB and PLT were measured at baseline and after the intervention. The PLT count decreased in the intervention group compared to the control group (173.38 ± 74.76 vs. 227.68 ± 86.58 103/mm3, F = 4.83, P = 0.03). No significant change was found on the levels of HCT and HB parameters between the two groups after the intervention. Omega-3 supplementation in HD patients may decrease the risk of forming blood clots in the blood vessels. Further studies are warranted.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	2589-9090 2589-9090
DOI:	10.1016/j.jtauto.2024.100233